We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is DaVita HealthCare (DVA) Down 5% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for DaVita HealthCare (DVA - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is DaVita HealthCare due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
DaVita Earnings Beat Estimates in Q2, Guidance Impressive
DaVita reported second-quarter 2019 adjusted earnings per share of $1.22, beating the Zacks Consensus Estimate of $1.10. The figure rose 16.2% on a year-over-year basis.
Total revenues in the quarter declined 1.5% year over year to $2.84 billion, missing the Zacks Consensus Estimate of $2.85 billion. Second-quarter adjusted operating income totaled $462 million, up 5.5% year over year.
Segment Details
Net dialysis and related lab patient service revenues in the second quarter totaled $2.63 billion, up 1.9% on a year-over-year basis. Other revenues were $6 million, up 20% from the year-ago quarter’s figure.
Per management, total U.S. dialysis treatments for the second quarter were 7,520,587, or an average of 96,418 treatments per day, representing a per day increase of 2.6% year over year.
Moreover, the company provided dialysis services at 2, 2,971 outpatient dialysis centers, of which 2, 2,723 centers were located in the United States and 248 in nine countries outside the United States.
The company has also gained from calcimimetics. In the quarter under review, DaVita generated operating income of approximately $40 million from calcimimetics.
For investors’ notice, the company has completed the divestment of the DaVita Medical Group (“DMG”) division to Optum, a subsidiary of UnitedHealth Group for a deal value of $4.34 billion.
Financial Condition
DaVita exited the second quarter with operating cash flow of $574 million.
Guidance
DaVita issued an impressive guidance for 2019.
Notably, the company now expects adjusted operating income between $1.64 billion and $1.70 billion. This reflects a significant increase from the earlier projected range of $1.54 billion to $1.64 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 8.16% due to these changes.
VGM Scores
At this time, DaVita HealthCare has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise DaVita HealthCare has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is DaVita HealthCare (DVA) Down 5% Since Last Earnings Report?
It has been about a month since the last earnings report for DaVita HealthCare (DVA - Free Report) . Shares have lost about 5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is DaVita HealthCare due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
DaVita Earnings Beat Estimates in Q2, Guidance Impressive
DaVita reported second-quarter 2019 adjusted earnings per share of $1.22, beating the Zacks Consensus Estimate of $1.10. The figure rose 16.2% on a year-over-year basis.
Total revenues in the quarter declined 1.5% year over year to $2.84 billion, missing the Zacks Consensus Estimate of $2.85 billion. Second-quarter adjusted operating income totaled $462 million, up 5.5% year over year.
Segment Details
Net dialysis and related lab patient service revenues in the second quarter totaled $2.63 billion, up 1.9% on a year-over-year basis. Other revenues were $6 million, up 20% from the year-ago quarter’s figure.
Per management, total U.S. dialysis treatments for the second quarter were 7,520,587, or an average of 96,418 treatments per day, representing a per day increase of 2.6% year over year.
Moreover, the company provided dialysis services at 2, 2,971 outpatient dialysis centers, of which 2, 2,723 centers were located in the United States and 248 in nine countries outside the United States.
The company has also gained from calcimimetics. In the quarter under review, DaVita generated operating income of approximately $40 million from calcimimetics.
For investors’ notice, the company has completed the divestment of the DaVita Medical Group (“DMG”) division to Optum, a subsidiary of UnitedHealth Group for a deal value of $4.34 billion.
Financial Condition
DaVita exited the second quarter with operating cash flow of $574 million.
Guidance
DaVita issued an impressive guidance for 2019.
Notably, the company now expects adjusted operating income between $1.64 billion and $1.70 billion. This reflects a significant increase from the earlier projected range of $1.54 billion to $1.64 billion.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates review. The consensus estimate has shifted 8.16% due to these changes.
VGM Scores
At this time, DaVita HealthCare has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise DaVita HealthCare has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.